Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-01
DOI
10.1002/jcp.29216
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mast Cells: A Double-Edged Sword in Cancer
- (2019) Afshin Derakhshani et al. IMMUNOLOGY LETTERS
- Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance
- (2019) Zohreh Rezaei et al. DNA AND CELL BIOLOGY
- Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?
- (2019) Fatemeh Vahidian et al. IMMUNOLOGY LETTERS
- Dynamic miRNA activity identifies therapeutic targets in trastuzumab-resistant HER2+ breast cancer
- (2018) Joseph T. Decker et al. BIOTECHNOLOGY AND BIOENGINEERING
- Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
- (2018) Philip E. Lammers et al. BRITISH JOURNAL OF CANCER
- Treatment of advanced HER2-positive breast cancer: 2018 and beyond
- (2018) Noam Pondé et al. CANCER TREATMENT REVIEWS
- p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial
- (2018) Jeff Sperinde et al. CLINICAL CANCER RESEARCH
- Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
- (2018) Martin Filipits et al. CLINICAL CANCER RESEARCH
- Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells
- (2018) Yuan-Chiang Chung et al. Scientific Reports
- HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer
- (2018) Alexandra Canonici et al. INVESTIGATIONAL NEW DRUGS
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- (2018) Babak Nami et al. Cancers
- PF-05280014: A Trastuzumab Biosimilar
- (2018) Julia Paik BIODRUGS
- PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
- (2018) Mark D. Pegram et al. BRITISH JOURNAL OF CANCER
- Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
- (2018) Takamasa Koga et al. LUNG CANCER
- p95HER2–T cell bispecific antibody for breast cancer treatment
- (2018) Irene Rius Ruiz et al. Science Translational Medicine
- Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
- (2018) Patrícia M. R. Pereira et al. Nature Communications
- SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
- (2017) Gulden Menderes et al. GYNECOLOGIC ONCOLOGY
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
- (2017) Matthew Sung et al. MOLECULAR CANCER THERAPEUTICS
- A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
- (2017) Ji-Youn Han et al. Cancer Research and Treatment
- Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
- (2017) S. Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
- (2016) An Na Seo et al. BRITISH JOURNAL OF CANCER
- Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry
- (2016) Yunting Zhu et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
- (2016) Gábor Tóth et al. mAbs
- Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation
- (2016) Marina Saisana et al. Oncotarget
- Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer
- (2016) Zhuo Wang et al. Oncotarget
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
- (2015) Eunhee G. Kim et al. Biomolecules & Therapeutics
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- The expression difference of insulin-like growth factor 1 receptor in breast cancers with or without diabetes
- (2015) Liu Ji-Yan et al. Journal of Cancer Research and Therapeutics
- The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma
- (2015) Priya Pai et al. Molecular Oncology
- β2-AR signaling controls trastuzumab resistance-dependent pathway
- (2015) D Liu et al. ONCOGENE
- Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer
- (2014) Jetzabel García-Parra et al. EUROPEAN JOURNAL OF CANCER
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Basal/HER2 breast carcinomas
- (2013) Begoña Martin-Castillo et al. CELL CYCLE
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
- (2013) D Raina et al. ONCOGENE
- Src activation by β-adrenoreceptors is a key switch for tumour metastasis
- (2013) Guillermo N. Armaiz-Pena et al. Nature Communications
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
- (2012) R Y Tsang et al. BRITISH JOURNAL OF CANCER
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
- (2011) Xiangyi Lu et al. BIOCHEMICAL PHARMACOLOGY
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
- (2011) P Todeschini et al. BRITISH JOURNAL OF CANCER
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- HER2 Therapy — An Abundance of Riches
- (2011) William J. Gradishar NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
- (2010) Jianhui Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unveiling the role of network and systems biology in drug discovery
- (2010) Albert Pujol et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
- (2009) S Chandarlapaty et al. ONCOGENE
- Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase
- (2009) E. S. Ehrlich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
- (2008) H Korkaya et al. ONCOGENE
- Development and application of Hsp90 inhibitors
- (2007) D SOLIT DRUG DISCOVERY TODAY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search